Alternative Data for Codexis
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 36 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,358 | Sign up | Sign up | Sign up |
| X Followers | N/A | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 37 | Sign up | Sign up | Sign up |
| Linkedin Employees | 241 | Sign up | Sign up | Sign up |
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics.
| Price | $2.46 |
| Target Price | Sign up |
| Volume | 773,940 |
| Market Cap | $224M |
| Year Range | $0.98 - $2.85 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
Codexis, Inc. Q4 2025 Earnings Call SummaryMarch 11 - Yahoo Entertainment |
|
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsMarch 11 - GlobeNewswire |
|
Codexis Achieves ISO 9001:2015 CertificationFebruary 9 - Benzinga |
|
 |
Codexis signs evaluation agreement with AxolabsJanuary 7 - Thefly.com |
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
 |
Which stocks are moving on Thursday?March 12 - ChartMill |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 15M | 2.1M | 13M | -8.7M | -8M | -0.100 |
| Q4 '25 | 39M | 7.1M | 32M | 9.6M | 17M | 0.143 |
| Q3 '25 | 8.6M | 2.5M | 6.1M | -20M | -16M | -0.220 |
| Q2 '25 | 15M | 2.1M | 13M | -13M | -12M | -0.160 |
| Q1 '25 | 7.5M | 2.7M | 4.8M | -21M | -19M | -0.250 |
Insider Transactions View All
| Lutz Stefan filed to sell 130,421 shares at $1.1. February 25 '26 |
| MOORE ALISON filed to sell 250,506 shares at $1.3. February 9 '26 |
| Erbez Georgia filed to sell 66,810 shares at $1.3. February 9 '26 |
| Lutz Stefan filed to sell 136,283 shares at $1.3. February 9 '26 |
| Lutz Stefan filed to sell 138,775 shares at $1.7. January 8 '26 |
Similar companies
Read more about Codexis (CDXS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Codexis
The Market Cap of Codexis is $224M.
Currently, the price of one share of Codexis stock is $2.46.
The CDXS stock price chart above provides a comprehensive visual representation of Codexis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Codexis shares. Our platform offers an up-to-date CDXS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Codexis (CDXS) does not offer dividends to its shareholders. Investors interested in Codexis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Codexis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
